Listed by the USPTO as ZEMAN, ROBERT A
Tech Center 1700 • Art Units: 1645 1792
This examiner grants 54% of resolved cases
ZEMAN, ROBERT A works in Tech Center 1700 and Art Unit 1645. Across 794 resolved cases, the allowance rate is 54.4%, the interview lift is 27.7%, and the median time to allowance is 1340 days. The substantial case record supports a moderate allowance assessment, while the interview figure identifies a meaningful prosecution lever.
The listed companies are Arizona Board of Regents on Behalf of Arizona State University, The Board of Trustees of the University of Illinois, and Intervet Inc. The listed firms are QUARLES & BRADY LLP, MYERS BIGEL, P.A., and PA - BOZICEVIC FIELD & FRANCIS LLP. Practitioners should account for both the interview association and the extended median timing.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18872768 | STAPHYLOCOCCUS AUREUS VACCINE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18531938 | METHOD TO PROVIDE LONG-LASTING CLEANING | Final Rejection | The Procter & Gamble Company |
| 17750968 | VACCINE AND METHODS FOR DETECTING AND PREVENTING FILARIASIS | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17601051 | MULTIVALENT VACCINES DERIVED FROM KLEBSIELLA OUTER MEMBRANE PROTEINS | Non-Final OA | University of Pittsburgh-Of the Commonwealth System of Higher Education |
| 18270611 | METHODS AND COMPOSITION FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Final Rejection | The General Hospital Corporation |
| 18826610 | ENGINEERED BACTERIAL RIBOSOME COMPOSITIONS AND METHODS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18484980 | STREPTOCOCCUS THERMOPHILUS STARTER STRAIN | Final Rejection | DSM IP Assets B.V. |
| 17924064 | Methods for Verification of Drug Levels Using Dried Blood Samples | Non-Final OA | Sanofi |
| 18873753 | VACCINE FOR PROTECTION AGAINST LEPTOSPIRA SEROVAR ICTEROHAEMORRHAGIAE | Non-Final OA | INTERVET INC. |
| 17641031 | COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION | Final Rejection | INTERVET INC. |
| 16347861 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST LYME DISEASE | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.4% of resolved applications examined by Robert A Zeman were allowed (794 resolved cases), compared with 49.4% across Art Unit 1645 over the last five years.
This examiner's interview lift is +27.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Robert A Zeman took 1,340 days on average from filing to allowance.
Robert A Zeman examines applications in Art Unit 1645 in Tech Center 1700 (Chemistry & Materials).